Arrowhead Pharmaceuticals, Inc.

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

The first clinical data from CRISPR Therapeutics’ in vivo gene-editing candidate, CTX310, look promising, with steep drops in low-density lipoprotein (LDL)-cholesterol and triglyceride levels. The r

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

Metabolic disease alliances have picked up as companies try to find a spot in the growing obesity market, and earlier this decade the COVID-19 pandemic drove a short-lived uptick in infectious disea